The Ark Genomic Revolution UCITS ETF AccumUSD (Ticker: IT:ARKG) is an innovative financial instrument designed to capture the explosive growth and transformative potential within the genomics sector. This exchange-traded fund (ETF) is strategically crafted for investors seeking exposure to advancements in genomic science, a niche that is poised to redefine healthcare, agriculture, and overall quality of life through cutting-edge technologies. As a sector-focused ETF, IT:ARKG meticulously curates a portfolio of companies at the forefront of genomic innovations, including those involved in gene editing, DNA sequencing, bioinformatics, and molecular diagnostics.
The ETF's thematic concentration on genomic advancements positions it uniquely within the market, offering investors a targeted approach to capitalize on the anticipated breakthroughs and commercial applications in personalized medicine and biotechnology. With a commitment to identifying and investing in companies that are leading the genomic revolution, Ark Genomic Revolution UCITS ETF AccumUSD provides a dynamic investment vehicle for those who believe in the transformative power of science and technology. By investing in IT:ARKG, stakeholders are not only tapping into a sector with significant growth potential but also contributing to the future of healthcare and scientific discovery.
Asset Class
Equity
Region
Global
Issuer
ARK
Index Tracked
No Underlying Index
Ticker Symbol
IT:ARKG
Ark Genomic Revolution Ucits ETF AccumUSD (ARKG) Fund Flow Chart
Ark Genomic Revolution Ucits ETF AccumUSD (ARKG) 1 year Net Flows: €4M
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.